source
- GSK receives accelerated FDA approval for oral lung cancer drug neladalkibGSK announced that the U.S. Food and Drug Administration granted accelerated approval to its oral lung cancer therapy neladalkib. The approval comes as part of the company's $10.6 billion acquisit…
- FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B, Senate votes on FDA commissionerThe FDA has denied the application for ivonescimab as a treatment for lung cancer, halting its development for that indication. Johnson & Johnson announced a deal to purchase Ollin Biosciences, a…